ReviewDrug design, development and therapy2026
Nanoparticle-Mediated PPAR Modulation of Macrophage Polarization in Radiation Enteritis: A Narrative Review.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation enteritis (RE) is a frequent and clinically important adverse effect of abdominal radiotherapy, characterized by acute inflammatory injury and longer-term fibrotic remodeling of the intestinal tract. Most patients receiving pelvic or abdominal irradiation experience measurable worsening of intestinal function. Macrophages orchestrate RE pathogenesis: tissue injury initially triggers a pro-inflammatory M1 phase that amplifies damage, followed by an M2 phase that promotes repair. Peroxisome proliferator-activated receptors (PPARs) have emerged as key regulators of macrophage polarization, with PPARγ playing a prominent role in promoting anti-inflammatory and tissue-restorative responses. This review explores the molecular mechanisms linking macrophage polarization and PPAR signaling in RE, reviews current PPAR-targeted therapies, and describes nanotechnology-based strategies for targeted intestinal delivery of PPAR modulators. We discuss how PPAR agonists modulate immune responses and how formulations engineered for localized intestinal activity may reduce systemic adverse effects. We also highlight progress in nanoparticle design, including carriers responsive to pH or reactive oxygen species and ligand-coated systems (e.g. hyaluronic acid or mannose) that target macrophages, thereby enhancing therapeutic delivery and cellular uptake. Finally, we summarize emerging omics-based approaches (single-cell transcriptomics, spatial profiling, and artificial-intelligence-driven design) that are accelerating the identification of novel therapeutic targets and informing the development of precision nanomedicines for RE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.